It came as the FTSE 100 giant revealed a rise in sales as weakness in its vaccine division was offset by growth in speciality ...

In an interview with Dr. Phil, the Kennedy offered false information about vaccine oversight and revealed a lack of understanding of new drug approvals.

The head of the Food and Drug Administration said Tuesday that the agency is now looking at whether it will still approve COVID-19 vaccines for next winter, citing a lack of data on booster shots.

In an interview with Dr. Phil, the health secretary offered false information about vaccine oversight and revealed a lack of ...

Dr. Marty Makary has been outspoken about vaccine mandates and other public health measures, so how does the Food and Drug ...

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

FDA vaccine oversight is shifting, with increased scrutiny and mixed messaging sparking concerns among health experts.

The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine -- the nation's only traditional ...

Among other things, Makary breaks some news here by stating, for the first time, that there will be no significant ...

While Vaxart can proceed with its study, fellow COVID-19 vaccine developers GeoVax and Novavax continue to be hamstrung by ...

There is common ground. Most adults favor: Preventing chronic diseases (Republicans 86%, Democrats 91%) Protecting against ...